Search
for
Sort by
Research 211–240 of 1000+
- Therapeutic expansion of JAK inhibitors in Chinese dermatological practice: beyond atopic dermatitis to novel autoimmune frontiers
- Real‐World Outcomes and Safety of JAK Inhibitors in Paediatric Alopecia Areata: A Retrospective Multicentre Study
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
- JAK INHIBITORS IN THE PATHOGENESIS OF ALOPECIA AREATA
- JAK INHIBITORS IN THE PATHOGENESIS OF ALOPECIA AREATA
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- Perceived Efficacy and Risks of Janus Kinase Inhibitors in Pediatric and Young Adult Alopecia Areata: A Cross‐Sectional Survey
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- 77200 Infections and Therapy Lapses Predominate as Flare Triggers on Oral JAK Inhibitors for Alopecia Areata: A Retrospective Cohort Study
- 73571 The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study
- Janus Kinase (JAK) Inhibitors in Dermatology: An Update and Critical Review
- Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- BH20 An unintended sequela of hair regrowth: severe Janus kinase inhibitor-associated acneiform eruption in alopecia areata
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study
- Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment
- Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata
- Image 1_Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata.pdf
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Biologic Therapies and Small-Molecule Inhibitors for Dissecting Cellulitis of the Scalp: A Systematic Review
- JAK Inhibitors in the Treatment of Alopecia Areata: Efficacy, Safety, and Long-term Outcomes
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)